On 29 January 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 29 January 2009 to 5 August 2009.
Since the announcement as of 2 March 2009, the following transactions have been made under the programme:
|
|
Number of
shares |
Average purchase
price |
Transaction value,
DKK |
|
Accumulated, last
announcement |
1,660,000 |
|
504,426,150 |
|
2 March 2009 |
75,000 |
280.12 |
21,009,000 |
|
3 March 2009 |
80,000 |
273.59 |
21,887,120 |
|
4 March 2009 |
75,000 |
273.64 |
20,523,000 |
|
5 March 2009 |
75,000 |
274.70 |
20,602,500 |
|
6 March 2009 |
75,000 |
260.92 |
19,569,000 |
|
Accumulated under the
programme |
2,040,000 |
|
608,016,770 |
Transactions related to Novo Nordisk's incentive programmes have resulted in an increase of 48,117 B-shares in Novo Nordisk's holding of treasury shares. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 26,892,552 treasury shares, corresponding to 4.2% of the share capital. The total amount of shares in the company is 634,000,000 including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Further information:
|
Media: |
Investors: |
|
|
|
|
Outside North America: |
Outside North America: |
|
Mette Kruse Danielsen |
Mads Veggerby Lausten |
|
Tel: (+45) 4442 3883 |
Tel: (+45) 4443 7919 |
|
|
|
|
|
Kasper Roseeuw Poulsen |
|
|
Tel: 4442 4471 |
|
|
|
|
|
|
|
In North America: |
In North America: |
|
Sean Clements |
Hans Rommer |
|
Tel: (+1) 609 514 8316 |
Tel: (+1) 609 919 7937 |
Company Announcement no 13 / 2009
